Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Shares Issued (2018 - 2025)

Neurogene's Shares Issued history spans 6 years, with the latest figure at $20.6 million for Q4 2025.

  • For Q4 2025, Shares Issued changed N/A year-over-year to $20.6 million; the TTM value through Dec 2025 reached $30.4 million, changed N/A, while the annual FY2025 figure was $30.4 million, N/A changed from the prior year.
  • Shares Issued reached $20.6 million in Q4 2025 per NGNE's latest filing, up from $9.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $92.2 million in Q4 2023 to a low of -$1.0 million in Q3 2024.
  • Average Shares Issued over 3 years is $11.2 million, with a median of $112000.0 recorded in 2023.
  • The largest YoY upside for Shares Issued was 1975.0% in 2024 against a maximum downside of 3082.86% in 2024.
  • A 3-year view of Shares Issued shows it stood at $92.2 million in 2023, then crashed by 101.13% to -$1.0 million in 2024, then skyrocketed by 2071.26% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Shares Issued are $20.6 million (Q4 2025), $9.7 million (Q3 2025), and $68000.0 (Q2 2025).